HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
Identifieur interne : 002A93 ( PubMed/Checkpoint ); précédent : 002A92; suivant : 002A94HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
Auteurs : Kelly E. Seaton [États-Unis] ; Lamar Ballweber [États-Unis] ; Audrey Lan [États-Unis] ; Michele Donathan [États-Unis] ; Sean Hughes [États-Unis] ; Lucia Vojtech [États-Unis] ; M Anthony Moody [États-Unis] ; Hua-Xin Liao [États-Unis] ; Barton F. Haynes [États-Unis] ; Christine G. Galloway [États-Unis] ; Barbra A. Richardson [États-Unis] ; Salim Abdool Karim [États-Unis] ; Charlene S. Dezzutti [États-Unis] ; M Juliana Mcelrath [États-Unis] ; Georgia D. Tomaras [États-Unis] ; Florian Hladik [États-Unis]Source :
- PloS one [ 1932-6203 ] ; 2014.
Descripteurs français
- KwdFr :
- Analyse de variance, Anti-infectieux (immunologie), Anti-infectieux (usage thérapeutique), Anticorps anti-VIH (immunologie), Femelle, Humains, Immunité muqueuse (), Immunité muqueuse (immunologie), Immunoglobuline A (immunologie), Immunoglobuline G (immunologie), Infections à VIH (), Infections à VIH (diagnostic), Infections à VIH (immunologie), Produits du gène env du virus de l'immunodéficience humaine (immunologie), Projets pilotes, Protéine d'enveloppe gp120 du VIH (immunologie), Prélèvement biologique (), Prélèvement biologique (instrumentation), République d'Afrique du Sud, Sécrétions corporelles (immunologie), Sécrétions corporelles (virologie), Séronégativité VIH (immunologie), Séropositivité VIH (immunologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), Vagin (immunologie), Vagin (virologie), Études de cohortes.
- MESH :
- diagnostic : Infections à VIH.
- immunologie : Anti-infectieux, Anticorps anti-VIH, Immunité muqueuse, Immunoglobuline A, Immunoglobuline G, Infections à VIH, Produits du gène env du virus de l'immunodéficience humaine, Protéine d'enveloppe gp120 du VIH, Sécrétions corporelles, Séronégativité VIH, Séropositivité VIH, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Vagin.
- usage thérapeutique : Anti-infectieux, Prélèvement biologique.
- virologie : Sécrétions corporelles, Vagin.
- Analyse de variance, Femelle, Humains, Immunité muqueuse, Infections à VIH, Projets pilotes, Prélèvement biologique, République d'Afrique du Sud, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études de cohortes.
- Wicri :
- geographic : Afrique du Sud.
English descriptors
- KwdEn :
- Analysis of Variance, Anti-Infective Agents (immunology), Anti-Infective Agents (therapeutic use), Bodily Secretions (immunology), Bodily Secretions (virology), Cohort Studies, Female, HIV Antibodies (immunology), HIV Envelope Protein gp120 (immunology), HIV Infections (diagnosis), HIV Infections (immunology), HIV Infections (prevention & control), HIV Seronegativity (immunology), HIV Seropositivity (immunology), HIV-1 (drug effects), HIV-1 (immunology), Humans, Immunity, Mucosal (drug effects), Immunity, Mucosal (immunology), Immunoglobulin A (immunology), Immunoglobulin G (immunology), Pilot Projects, South Africa, Specimen Handling (instrumentation), Specimen Handling (methods), Vagina (immunology), Vagina (virology), env Gene Products, Human Immunodeficiency Virus (immunology).
- MESH :
- chemical , immunology : Anti-Infective Agents, HIV Antibodies, HIV Envelope Protein gp120, Immunoglobulin A, Immunoglobulin G, env Gene Products, Human Immunodeficiency Virus.
- chemical , therapeutic use : Anti-Infective Agents.
- geographic : South Africa.
- diagnosis : HIV Infections.
- drug effects : HIV-1, Immunity, Mucosal.
- immunology : Bodily Secretions, HIV Infections, HIV Seronegativity, HIV Seropositivity, HIV-1, Immunity, Mucosal, Vagina.
- instrumentation : Specimen Handling.
- methods : Specimen Handling.
- prevention & control : HIV Infections.
- virology : Bodily Secretions, Vagina.
- Analysis of Variance, Cohort Studies, Female, Humans, Pilot Projects.
Abstract
Many participants in microbicide trials remain uninfected despite ongoing exposure to HIV-1. Determining the emergence and nature of mucosal HIV-specific immune responses in such women is important, since these responses may contribute to protection and could provide insight for the rational design of HIV-1 vaccines.
DOI: 10.1371/journal.pone.0101863
PubMed: 25054205
Affiliations:
- États-Unis
- Caroline du Nord, Pennsylvanie, Washington (État), État de New York
- Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25054205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.</title><author><name sortKey="Seaton, Kelly E" sort="Seaton, Kelly E" uniqKey="Seaton K" first="Kelly E" last="Seaton">Kelly E. Seaton</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Ballweber, Lamar" sort="Ballweber, Lamar" uniqKey="Ballweber L" first="Lamar" last="Ballweber">Lamar Ballweber</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Lan, Audrey" sort="Lan, Audrey" uniqKey="Lan A" first="Audrey" last="Lan">Audrey Lan</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Donathan, Michele" sort="Donathan, Michele" uniqKey="Donathan M" first="Michele" last="Donathan">Michele Donathan</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hughes, Sean" sort="Hughes, Sean" uniqKey="Hughes S" first="Sean" last="Hughes">Sean Hughes</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Vojtech, Lucia" sort="Vojtech, Lucia" uniqKey="Vojtech L" first="Lucia" last="Vojtech">Lucia Vojtech</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Moody, M Anthony" sort="Moody, M Anthony" uniqKey="Moody M" first="M Anthony" last="Moody">M Anthony Moody</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Liao, Hua Xin" sort="Liao, Hua Xin" uniqKey="Liao H" first="Hua-Xin" last="Liao">Hua-Xin Liao</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Galloway, Christine G" sort="Galloway, Christine G" uniqKey="Galloway C" first="Christine G" last="Galloway">Christine G. Galloway</name><affiliation wicri:level="2"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Richardson, Barbra A" sort="Richardson, Barbra A" uniqKey="Richardson B" first="Barbra A" last="Richardson">Barbra A. Richardson</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Karim, Salim Abdool" sort="Karim, Salim Abdool" uniqKey="Karim S" first="Salim Abdool" last="Karim">Salim Abdool Karim</name><affiliation wicri:level="2"><nlm:affiliation>CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Dezzutti, Charlene S" sort="Dezzutti, Charlene S" uniqKey="Dezzutti C" first="Charlene S" last="Dezzutti">Charlene S. Dezzutti</name><affiliation wicri:level="2"><nlm:affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M Juliana" last="Mcelrath">M Juliana Mcelrath</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Tomaras, Georgia D" sort="Tomaras, Georgia D" uniqKey="Tomaras G" first="Georgia D" last="Tomaras">Georgia D. Tomaras</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hladik, Florian" sort="Hladik, Florian" uniqKey="Hladik F" first="Florian" last="Hladik">Florian Hladik</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25054205</idno><idno type="pmid">25054205</idno><idno type="doi">10.1371/journal.pone.0101863</idno><idno type="wicri:Area/PubMed/Corpus">002403</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002403</idno><idno type="wicri:Area/PubMed/Curation">002393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002393</idno><idno type="wicri:Area/PubMed/Checkpoint">002393</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002393</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.</title><author><name sortKey="Seaton, Kelly E" sort="Seaton, Kelly E" uniqKey="Seaton K" first="Kelly E" last="Seaton">Kelly E. Seaton</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Ballweber, Lamar" sort="Ballweber, Lamar" uniqKey="Ballweber L" first="Lamar" last="Ballweber">Lamar Ballweber</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Lan, Audrey" sort="Lan, Audrey" uniqKey="Lan A" first="Audrey" last="Lan">Audrey Lan</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Donathan, Michele" sort="Donathan, Michele" uniqKey="Donathan M" first="Michele" last="Donathan">Michele Donathan</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hughes, Sean" sort="Hughes, Sean" uniqKey="Hughes S" first="Sean" last="Hughes">Sean Hughes</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Vojtech, Lucia" sort="Vojtech, Lucia" uniqKey="Vojtech L" first="Lucia" last="Vojtech">Lucia Vojtech</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Moody, M Anthony" sort="Moody, M Anthony" uniqKey="Moody M" first="M Anthony" last="Moody">M Anthony Moody</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Liao, Hua Xin" sort="Liao, Hua Xin" uniqKey="Liao H" first="Hua-Xin" last="Liao">Hua-Xin Liao</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Galloway, Christine G" sort="Galloway, Christine G" uniqKey="Galloway C" first="Christine G" last="Galloway">Christine G. Galloway</name><affiliation wicri:level="2"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Richardson, Barbra A" sort="Richardson, Barbra A" uniqKey="Richardson B" first="Barbra A" last="Richardson">Barbra A. Richardson</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Karim, Salim Abdool" sort="Karim, Salim Abdool" uniqKey="Karim S" first="Salim Abdool" last="Karim">Salim Abdool Karim</name><affiliation wicri:level="2"><nlm:affiliation>CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Dezzutti, Charlene S" sort="Dezzutti, Charlene S" uniqKey="Dezzutti C" first="Charlene S" last="Dezzutti">Charlene S. Dezzutti</name><affiliation wicri:level="2"><nlm:affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M Juliana" last="Mcelrath">M Juliana Mcelrath</name><affiliation wicri:level="4"><nlm:affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Tomaras, Georgia D" sort="Tomaras, Georgia D" uniqKey="Tomaras G" first="Georgia D" last="Tomaras">Georgia D. Tomaras</name><affiliation wicri:level="2"><nlm:affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke Human Vaccine Institute, Durham, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hladik, Florian" sort="Hladik, Florian" uniqKey="Hladik F" first="Florian" last="Hladik">Florian Hladik</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Anti-Infective Agents (immunology)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Bodily Secretions (immunology)</term><term>Bodily Secretions (virology)</term><term>Cohort Studies</term><term>Female</term><term>HIV Antibodies (immunology)</term><term>HIV Envelope Protein gp120 (immunology)</term><term>HIV Infections (diagnosis)</term><term>HIV Infections (immunology)</term><term>HIV Infections (prevention & control)</term><term>HIV Seronegativity (immunology)</term><term>HIV Seropositivity (immunology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (immunology)</term><term>Humans</term><term>Immunity, Mucosal (drug effects)</term><term>Immunity, Mucosal (immunology)</term><term>Immunoglobulin A (immunology)</term><term>Immunoglobulin G (immunology)</term><term>Pilot Projects</term><term>South Africa</term><term>Specimen Handling (instrumentation)</term><term>Specimen Handling (methods)</term><term>Vagina (immunology)</term><term>Vagina (virology)</term><term>env Gene Products, Human Immunodeficiency Virus (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de variance</term><term>Anti-infectieux (immunologie)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Anticorps anti-VIH (immunologie)</term><term>Femelle</term><term>Humains</term><term>Immunité muqueuse ()</term><term>Immunité muqueuse (immunologie)</term><term>Immunoglobuline A (immunologie)</term><term>Immunoglobuline G (immunologie)</term><term>Infections à VIH ()</term><term>Infections à VIH (diagnostic)</term><term>Infections à VIH (immunologie)</term><term>Produits du gène env du virus de l'immunodéficience humaine (immunologie)</term><term>Projets pilotes</term><term>Protéine d'enveloppe gp120 du VIH (immunologie)</term><term>Prélèvement biologique ()</term><term>Prélèvement biologique (instrumentation)</term><term>République d'Afrique du Sud</term><term>Sécrétions corporelles (immunologie)</term><term>Sécrétions corporelles (virologie)</term><term>Séronégativité VIH (immunologie)</term><term>Séropositivité VIH (immunologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term><term>Vagin (immunologie)</term><term>Vagin (virologie)</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Infective Agents</term><term>HIV Antibodies</term><term>HIV Envelope Protein gp120</term><term>Immunoglobulin A</term><term>Immunoglobulin G</term><term>env Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Immunity, Mucosal</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anti-infectieux</term><term>Anticorps anti-VIH</term><term>Immunité muqueuse</term><term>Immunoglobuline A</term><term>Immunoglobuline G</term><term>Infections à VIH</term><term>Produits du gène env du virus de l'immunodéficience humaine</term><term>Protéine d'enveloppe gp120 du VIH</term><term>Sécrétions corporelles</term><term>Séronégativité VIH</term><term>Séropositivité VIH</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Vagin</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Bodily Secretions</term><term>HIV Infections</term><term>HIV Seronegativity</term><term>HIV Seropositivity</term><term>HIV-1</term><term>Immunity, Mucosal</term><term>Vagina</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Specimen Handling</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Specimen Handling</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term><term>Prélèvement biologique</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Sécrétions corporelles</term><term>Vagin</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bodily Secretions</term><term>Vagina</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Pilot Projects</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de variance</term><term>Femelle</term><term>Humains</term><term>Immunité muqueuse</term><term>Infections à VIH</term><term>Projets pilotes</term><term>Prélèvement biologique</term><term>République d'Afrique du Sud</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études de cohortes</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many participants in microbicide trials remain uninfected despite ongoing exposure to HIV-1. Determining the emergence and nature of mucosal HIV-specific immune responses in such women is important, since these responses may contribute to protection and could provide insight for the rational design of HIV-1 vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25054205</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>24</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.</ArticleTitle><Pagination><MedlinePgn>e101863</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0101863</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many participants in microbicide trials remain uninfected despite ongoing exposure to HIV-1. Determining the emergence and nature of mucosal HIV-specific immune responses in such women is important, since these responses may contribute to protection and could provide insight for the rational design of HIV-1 vaccines.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We first conducted a pilot study to compare three sampling devices (Dacron swabs, flocked nylon swabs and Merocel sponges) for detection of HIV-1-specific IgG and IgA antibodies in vaginal secretions. IgG antibodies from HIV-1-positive women reacted broadly across the full panel of eight HIV-1 envelope (Env) antigens tested, whereas IgA antibodies only reacted to the gp41 subunit. No Env-reactive antibodies were detected in the HIV-negative women. The three sampling devices yielded equal HIV-1-specific antibody titers, as well as total IgG and IgA concentrations. We then tested vaginal Dacron swabs archived from 57 HIV seronegative women who participated in a microbicide efficacy trial in Southern Africa (HPTN 035). We detected vaginal IgA antibodies directed at HIV-1 Env gp120/gp140 in six of these women, and at gp41 in another three women, but did not detect Env-specific IgG antibodies in any women.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Vaginal secretions of HIV-1 infected women contained IgG reactivity to a broad range of Env antigens and IgA reactivity to gp41. In contrast, Env-binding antibodies in the vaginal secretions of HIV-1 uninfected women participating in the microbicide trial were restricted to the IgA subtype and were mostly directed at HIV-1 gp120/gp140.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seaton</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballweber</LastName><ForeName>Lamar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donathan</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojtech</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moody</LastName><ForeName>M Anthony</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Hua-Xin</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haynes</LastName><ForeName>Barton F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galloway</LastName><ForeName>Christine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Barbra A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Salim Abdool</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dezzutti</LastName><ForeName>Charlene S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElrath</LastName><ForeName>M Juliana</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomaras</LastName><ForeName>Georgia D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hladik</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068633</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AI064518</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AI067854</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068615</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI106707</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI069481</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068618</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1AI068618</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015483">HIV Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015699">HIV Envelope Protein gp120</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054299">env Gene Products, Human Immunodeficiency Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097729">gp140 envelope protein, Human immunodeficiency virus 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2000 Feb 1;164(3):1602-11</RefSource><PMID Version="1">10640781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Dec 15;206(12):1931-5</RefSource><PMID Version="1">22966121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2000 Sep 8;14(13):1917-20</RefSource><PMID Version="1">10997395</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2000 Nov 1;165(9):5170-6</RefSource><PMID Version="1">11046049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2001 Feb;107(3):341-9</RefSource><PMID Version="1">11160158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Feb 16;15(3):431-2</RefSource><PMID Version="1">11273233</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2001 Dec 1;184(11):1412-22</RefSource><PMID Version="1">11709783</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2002 Jun 28;296(5577):2354-60</RefSource><PMID Version="1">12089434</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2003 Mar 7;17(4):531-9</RefSource><PMID Version="1">12598773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2003 Sep 1;171(5):2671-83</RefSource><PMID Version="1">12928421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Diagn Lab Immunol. 1995 Jan;2(1):57-61</RefSource><PMID Version="1">7719914</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1995 Aug;96(2):867-76</RefSource><PMID Version="1">7635981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 1995 Jan;1(1):59-64</RefSource><PMID Version="1">7584954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1997 Apr 10;336(15):1072-8</RefSource><PMID Version="1">9091805</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 1997 Nov;3(11):1250-7</RefSource><PMID Version="1">9359700</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S51-5</RefSource><PMID Version="1">9581884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1998 Nov 1;102(9):1758-65</RefSource><PMID Version="1">9802890</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1999 Jan;179(1):59-67</RefSource><PMID Version="1">9841823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1999 Mar;179(3):538-47</RefSource><PMID Version="1">9952359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2004 Sep;20(9):972-88</RefSource><PMID Version="1">15585085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2005 Jan;79(2):1154-63</RefSource><PMID Version="1">15613343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV/AIDS Rep. 2006 Feb;3(1):26-31</RefSource><PMID Version="1">16522256</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Cell Biol. 2006 Oct;84(5):482-5</RefSource><PMID Version="1">16942489</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 2006 Sep 30;353(2):268-82</RefSource><PMID Version="1">17039602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2008 Jan;82(1):115-25</RefSource><PMID Version="1">17942537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2008 Jun;8(6):447-57</RefSource><PMID Version="1">18469831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2008 Aug 5;5(8):e157; discussion e157</RefSource><PMID Version="1">18684007</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Vaccine Immunol. 2008 Nov;15(11):1745-8</RefSource><PMID Version="1">18815234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2008 Dec;82(24):12449-63</RefSource><PMID Version="1">18842730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Nov 29;372(9653):1881-93</RefSource><PMID Version="1">19012954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Nov 29;372(9653):1894-905</RefSource><PMID Version="1">19012957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2009 Sep;2(5):412-26</RefSource><PMID Version="1">19587640</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Dec 3;361(23):2209-20</RefSource><PMID Version="1">19843557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2010 Apr 1;184(7):3648-55</RefSource><PMID Version="1">20208001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Jan 14;13(1):23-9</RefSource><PMID Version="1">10207541</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Reprod Immunol. 1999 Mar;42(2):93-106</RefSource><PMID Version="1">10221733</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2013 Mar;6(2):427-34</RefSource><PMID Version="1">22990624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2013 Apr;87(8):4185-201</RefSource><PMID Version="1">23365441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2013 May 10;340(6133):667</RefSource><PMID Version="1">23661729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2013 Jul;6(4):692-703</RefSource><PMID Version="1">23299618</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Jun 1;27(9):F13-20</RefSource><PMID Version="1">23775002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2013 Jul;87(14):7828-36</RefSource><PMID Version="1">23658446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Nov 28;369(22):2083-92</RefSource><PMID Version="1">24099601</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2014 Jan;7(1):46-56</RefSource><PMID Version="1">23591718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2014 May;88(9):5165-70</RefSource><PMID Version="1">24554654</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(3):e9920</RefSource><PMID Version="1">20360961</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2011 Feb;49(2):735-6</RefSource><PMID Version="1">21106793</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Apr 24;25(7):957-66</RefSource><PMID Version="1">21330907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2011 May;27(5):469-86</RefSource><PMID Version="1">21091128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2011 Jul;27(7):737-43</RefSource><PMID Version="1">21142412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6</RefSource><PMID Version="1">21690411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2011 Sep;85(18):9555-67</RefSource><PMID Version="1">21734046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mucosal Immunol. 2011 Sep;4(5):539-53</RefSource><PMID Version="1">21525865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(8):e23136</RefSource><PMID Version="1">21858008</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2011 Nov;85(21):11502-19</RefSource><PMID Version="1">21849452</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2011 Nov;85(21):11196-207</RefSource><PMID Version="1">21865397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(9):e23532</RefSource><PMID Version="1">21980336</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Nov 13;25(17):2089-97</RefSource><PMID Version="1">21832938</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Apr 5;366(14):1275-86</RefSource><PMID Version="1">22475592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Oct;206(8):1299-308</RefSource><PMID Version="1">22926009</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Nov 13;26(17):2155-63</RefSource><PMID Version="1">22948273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2000 Jun 16;14(9):1117-22</RefSource><PMID Version="1">10894275</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012634" MajorTopicYN="N">Bodily Secretions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015483" MajorTopicYN="N">HIV Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015699" MajorTopicYN="N">HIV Envelope Protein gp120</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018023" MajorTopicYN="N">HIV Seronegativity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006679" MajorTopicYN="N">HIV Seropositivity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013048" MajorTopicYN="N">Specimen Handling</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014621" MajorTopicYN="N">Vagina</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054299" MajorTopicYN="N">env Gene Products, Human Immunodeficiency Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4108330</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25054205</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0101863</ArticleId><ArticleId IdType="pii">PONE-D-14-10051</ArticleId><ArticleId IdType="pmc">PMC4108330</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Pennsylvanie</li><li>Washington (État)</li><li>État de New York</li></region><settlement><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Seaton, Kelly E" sort="Seaton, Kelly E" uniqKey="Seaton K" first="Kelly E" last="Seaton">Kelly E. Seaton</name></region><name sortKey="Ballweber, Lamar" sort="Ballweber, Lamar" uniqKey="Ballweber L" first="Lamar" last="Ballweber">Lamar Ballweber</name><name sortKey="Dezzutti, Charlene S" sort="Dezzutti, Charlene S" uniqKey="Dezzutti C" first="Charlene S" last="Dezzutti">Charlene S. Dezzutti</name><name sortKey="Donathan, Michele" sort="Donathan, Michele" uniqKey="Donathan M" first="Michele" last="Donathan">Michele Donathan</name><name sortKey="Galloway, Christine G" sort="Galloway, Christine G" uniqKey="Galloway C" first="Christine G" last="Galloway">Christine G. Galloway</name><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F" last="Haynes">Barton F. Haynes</name><name sortKey="Hladik, Florian" sort="Hladik, Florian" uniqKey="Hladik F" first="Florian" last="Hladik">Florian Hladik</name><name sortKey="Hughes, Sean" sort="Hughes, Sean" uniqKey="Hughes S" first="Sean" last="Hughes">Sean Hughes</name><name sortKey="Karim, Salim Abdool" sort="Karim, Salim Abdool" uniqKey="Karim S" first="Salim Abdool" last="Karim">Salim Abdool Karim</name><name sortKey="Lan, Audrey" sort="Lan, Audrey" uniqKey="Lan A" first="Audrey" last="Lan">Audrey Lan</name><name sortKey="Liao, Hua Xin" sort="Liao, Hua Xin" uniqKey="Liao H" first="Hua-Xin" last="Liao">Hua-Xin Liao</name><name sortKey="Mcelrath, M Juliana" sort="Mcelrath, M Juliana" uniqKey="Mcelrath M" first="M Juliana" last="Mcelrath">M Juliana Mcelrath</name><name sortKey="Moody, M Anthony" sort="Moody, M Anthony" uniqKey="Moody M" first="M Anthony" last="Moody">M Anthony Moody</name><name sortKey="Richardson, Barbra A" sort="Richardson, Barbra A" uniqKey="Richardson B" first="Barbra A" last="Richardson">Barbra A. Richardson</name><name sortKey="Tomaras, Georgia D" sort="Tomaras, Georgia D" uniqKey="Tomaras G" first="Georgia D" last="Tomaras">Georgia D. Tomaras</name><name sortKey="Vojtech, Lucia" sort="Vojtech, Lucia" uniqKey="Vojtech L" first="Lucia" last="Vojtech">Lucia Vojtech</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002A93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25054205
|texte= HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25054205" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |